Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | JAK1 | P23458 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2956149 | 0.92 | CSF1R (0.39) | CSF1RCHRNA7DHODHALDH1A1CYP1A2 | |
| SCHEMBL2952695 | 0.91 | LMNA (0.36) | CSF1RLMNAGAAGFERALDH1A1 | |
| SCHEMBL2956676 | 0.78 | CSF1R (0.38) | CSF1RCHRNA7LMNADHODHALDH1A1 | |
| SCHEMBL2958519 | 0.78 | LMNA (0.34) | LMNAGAAGFERCYP1A2CYP3A4 | |
| SCHEMBL2956929 | 0.78 | RAB9A (0.39) | CSF1RCHRNA7GAAPOLBMAPK1 | |
| SCHEMBL2949261 | 0.77 | IDO1 (0.39) | POLB | |
| SCHEMBL2958462 | 0.75 | CSF1R (0.39) | CSF1RCHRNA7LMNAJAK2JAK1 | |
| SCHEMBL2952198 | 0.75 | CSF1R (0.39) | CSF1RCHRNA7LMNADHODH | |
| SCHEMBL2950317 | 0.75 | CSF1R (0.39) | CSF1RCHRNA7JAK2JAK1GAA | |
| SCHEMBL2947364 | 0.74 | CHRNA7 (0.40) | CSF1RCHRNA7LMNADHODHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004025-A1 | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors | UCB PHARMA S.A. (BE) | 2006-01-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004025-A1 | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors | MAPK1, CNKSR1, ALK | CSF1R 412/4885CHRNA7 1817/4885LMNA 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.